Status:
ACTIVE_NOT_RECRUITING
[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients
Lead Sponsor:
Peking University Cancer Hospital & Institute
Conditions:
Prostate Cancer
Eligibility:
MALE
18-90 years
Phase:
NA
Brief Summary
To investigate the radioactive uptake of \[Al 18 F\]PSMA137 in PCa patients, and evaluate the ability of \[Al 18 F\]PSMA137 to detect PSMA overexpression in PCa patients (especially those with recurre...
Detailed Description
Prostate cancer (PCa) is the most common malignant tumor in the male reproductive system, and its prognosis and treatment mainly depend on the discovery of the primary disease and the early stage of m...
Eligibility Criteria
Inclusion
- Men over 18 years of age need to undergo \[Al18F\]PSMA137 PET/CT examination for suspected prostate cancer.
- The patients can fully understand and voluntarily participate in this experiment, and sign the informed consent.
Exclusion
- Significant hepatic or renal dysfunction;
- Patients with malignant tumors other than prostate cancer within 2 years;
- Ready to pregnant;
- The patient can not tolerate all clinical tests.
Key Trial Info
Start Date :
January 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 12 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04693169
Start Date
January 15 2021
End Date
December 12 2024
Last Update
January 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142